29.98

2.57% -0.79

Biolife Solutions Inc (BLFS)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Biolife Solutions Inc stock is traded at $29.98, with a volume of 2.61M. It is down -2.57% in the last 24 hours and up +17.25% over the past month. BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.

Previous Close:

$30.77

Open:

$30.36

24h Volume:

2.61M

Relative Volume:

2.62

Market Cap:

$1.46B

Revenue:

$96.21M

Net Income/Loss:

$-12.13M

P/E Ratio:

-95.78

EPS:

-0.313

Net Cash Flow:

$10.64M

1W Performance:

+2.85%

1M Performance:

+17.25%

6M Performance:

+20.55%

1Y Performance:

+34.68%

1-Day Range:

$29.92

$30.73

1-Week Range:

$28.54

$32.23

52-Week Range:

$17.86

$32.23

Biolife Solutions Inc Stock (BLFS) Company Profile

Name

Biolife Solutions Inc

Sector

Healthcare (1071)

Industry

Medical Instruments & Supplies (57)

Phone

(425) 401-1400

Address

3303 MONTE VILLA PARKWAY, BOTHELL, WA

Employee

155

Twitter

@biolifesol

Next Earnings Date

2026-08-06

Latest SEC Filings

BLFS's Discussions on Twitter

Compare BLFS vs ISRG, BDX, ALC, MDLN, RMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BLFS Biolife Solutions Inc	29.98	1.46B	96.21M	-12.13M	10.64M	-0.313
ISRG Intuitive Surgical Inc	337.50	120.92B	11.03B	3.16B	3.22B	8.7251
BDX Becton Dickinson Co	156.36	43.08B	21.37B	1.41B	3.07B	3.9437
ALC Alcon Inc	67.91	33.12B	10.63B	819.00M	1.59B	1.6577
MDLN Medline Inc	38.75	32.77B	29.14B	1.07B	1.05B	1.1956
RMD Resmed Inc	195.27	28.33B	5.54B	1.52B	1.74B	10.37

Biolife Solutions Inc Stock (BLFS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-22-25	Resumed	Stephens	Overweight
Sep-30-24	Initiated	H.C. Wainwright	Buy
Apr-04-24	Initiated	Jefferies	Buy
Jul-11-23	Initiated	Craig Hallum	Buy
Apr-25-22	Upgrade	Oppenheimer	Perform → Outperform
Oct-19-21	Initiated	B. Riley Securities	Buy
Oct-15-21	Resumed	Cowen	Outperform
May-14-21	Downgrade	The Benchmark Company	Buy → Hold
Mar-23-21	Upgrade	The Benchmark Company	Hold → Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight
Sep-22-20	Downgrade	Oppenheimer	Outperform → Perform
Sep-18-20	Initiated	Cowen	Outperform
Aug-11-20	Downgrade	The Benchmark Company	Buy → Hold
Jul-08-20	Reiterated	Maxim Group	Buy
Feb-24-20	Initiated	Lake Street	Buy
Feb-19-20	Initiated	The Benchmark Company	Buy
Feb-06-20	Resumed	B. Riley FBR	Buy
Jan-08-20	Initiated	Stephens	Overweight
Nov-21-19	Initiated	Oppenheimer	Outperform
Jul-22-19	Initiated	H.C. Wainwright	Buy
Nov-10-17	Reiterated	Maxim Group	Buy
Sep-19-17	Reiterated	Maxim Group	Buy
Jul-05-17	Upgrade	Janney	Neutral → Buy
Mar-10-17	Reiterated	Maxim Group	Buy
Jan-19-17	Initiated	Maxim Group	Buy

View All

Biolife Solutions Inc Stock (BLFS) Latest News

Jul 24, 2026

BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc.BLFS - The Malone Telegram

Jul 24, 2026

Repligen Corporation to Acquire BioLife Solutions for $1.5 Billion, Boosting Cell Therapy Market Presence - Kalkine Media

Jul 24, 2026

Repligen to buy BioLife Solutions (NASDAQ: BLFS) in $1.5B cash-and-stock deal - Stock Titan

Jul 24, 2026